Management of angiosarcoma

Budd, G. Thomas

doi:10.1007/s11912-002-0066-3

Cited by 87 publications

(60 citation statements)

References 41 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Angiosarcomas arise at various sites; in elderly people, these tumours commonly arise in the scalp and face 2 . Primary angiosarcoma of the ovary is extremely rare 3 , with only 35 cases being reported to date ( Table i).…”

Section: Introductionmentioning

confidence: 99%

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

et al. 2014

View full text Add to dashboard Cite

Our patient presented with advanced ovarian angiosarcoma and bone metastases and still achieved 7 years of progression-free survival after treatment with a gemcitabine-based regimen. Recently, MYC amplification was proposed to occur in a proportion of primary 31 and radiation-induced angiosarcomas 32 . Enhanced expression of c-Myc is an important mediator leading to disease development 33 . We therefore report our case and the results of retrospective MYC gene amplification and c-Myc protein expression analyses, discuss the relevance of those factors in terms of therapy and prognosis, and review the related literature. CASE DESCRIPTIONA 29-year-old woman was admitted to the emergency room with abdominal pain and fever. Abdominal palpation revealed rebound tenderness. Transvaginal ultrasonography revealed a cystic mass of approximately 9 cm in the right pelvis, within which several solid masses existed. The masses were recognized as blood clots or other artefacts unrelated to the tumour component. A small amount of ascites in the Douglas pouch was also observed.Laboratory data revealed a white blood cell count of 9320×10 3 /μL, with 85.6% neutrophils, and 2.30 mg/dL serum C-reactive protein. On the following day, serum C-reactive protein increased to 11.22 mg/dL, indicating a level of inflammation.Clinically, a rupture or torsion of the right ovarian tumour with acute peritonitis was suspected. Intravenous administration of ceftriaxone sodium hydrate 2 g daily was initiated and continued for 3 days.Magnetic resonance imaging revealed a cystic right ovarian tumour whose cystic portion contained a fluid or blood component [ Figure 1(A,B)]. Computed tomography revealed low-density areas in several bones, suggestive of osteolytic bone metastases [ Figure 2(A)]. We also examined the tumour markers cancer antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen, whose ABSTRACT Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabinebased chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.

show abstract

Section: Introductionmentioning

confidence: 99%

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Angiosarcomas represent a small subgroup of soft tissue sarcomas that typically occur on the scalp or face 7 and in postradiation fields, 8 although they may occur at other sites as well. 9,10 Although the response rates of soft tissue sarcomas to chemotherapy in general is Ͻ 40%, reports suggest that paclitaxel may be uniquely effective in angiosarcomas. In a Phase I trial of continuous infusion paclitaxel, 1 of 1 patient with angiosarcoma obtained a dramatic partial response (PR) that persisted for 12 months.…”

mentioning

confidence: 99%

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz

Haddad

2005

Cancer

188

105

View full text Add to dashboard Cite

BACKGROUNDPaclitaxel has unique activity in angiosarcomas of the face and scalp, but its activity in angiosarcomas originating at other sites is less well defined. Paclitaxel and pegylated‐liposomal doxorubicin (PLD) are highly effective in Kaposi sarcoma (KS). Because of the efficacy of PLD in soft tissue sarcoma in general, and in KS in particular, coupled with potential similarities in KS and angiosarcoma, and the apparent activity of paclitaxel in angiosarcomas, the authors treated patients with angiosarcoma with either paclitaxel or PLD as initial chemotherapy.METHODSTo better define the efficacy of these agents in angiosarcoma, the authors reviewed their experience with paclitaxel and PLD in patients with angiosarcoma treated between 1994 and 2004.RESULTSThey identified seven patients with angiosarcoma treated with paclitaxel, and six treated with PLD. Only one patient in the series had an angiosarcoma of the scalp. Two patients receiving paclitaxel had received previous therapy with PLD, and four of six patients treated with PLD had previously received paclitaxel. Of the eight patients treated with paclitaxel, five had major responses (three had partial responses [PR] and two had complete disease remission [CR]) and three had progressive disease (PD). Of the 6 patients who received PLD, 3 had a PR for 6, 19, and >20 months, respectively, 2 had stable disease for 7 and 11 months, respectively, and 1 had PD.CONCLUSIONSThe current study demonstrated the activity of PLD (five of six patients experienced clinical benefit) and extended the data on paclitaxel in angiosarcoma, both of the face and scalp, as well as angiosarcoma originating at other sites. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…Angiosarcomas are uncommon soft tissue sarcomas that can arise in a variety of locations, including liver, spleen, skin, breast, and endocrine organs. [9][10][11] Among these tumors, specific subtypes are associated with a variety of risk factors, such as occupational exposure to vinyl chloride for hepatic angiosarcoma, 12,13 radiation therapy for mammary angiosarcoma, [14][15][16][17][18][19] HIV-1 infection in the case of Kaposi sarcoma, 20 and heritable defects in the VHL tumor suppressor gene in human infantile angiosarcomas and hemangiomas. 21 Exposure to ionizing radiation seems to be a shared risk factor for development of HSA in dogs.…”

mentioning

confidence: 99%

“…22 As is true for canine HSA, treatment of human angiosarcomas can be challenging and is frequently unrewarding. 9,11,23 In part, the paucity of effective treatments for endothelial cancers is due to the lack of appropriate reagents to study these diseases. [24][25][26][27][28][29] Thus, our objective was to establish and characterize a cohort of canine HSA cell lines that could be used to explore the molecular and cellular features of this disease and that could serve as a resource to explore comparative aspects of canine and human endothelial tumors for therapeutic development.…”

mentioning

confidence: 99%

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Fosmire

Dickerson

Scott

et al. 2004

Laboratory Investigation

123

View full text Add to dashboard Cite

Hemangiosarcoma (HSA) is a common untreatable cancer of dogs that resembles human angiosarcoma. Detailed studies of these diseases have been historically hindered by the paucity of suitable reagents. Here, we show that expression of CD117 (c-Kit) can distinguish primitive (malignant) from mature (benign) proliferative endothelial lesions, and we describe eight independent cell lines derived from canine HSA explants. Endothelial origin was confirmed by sustained expression of surface CD105 (endoglin), CD146 (MUC18), and CD51/CD61 (a v b 3 integrin). The cell lines showed anchorage-independent growth and were motile and invasive when cultured on a basement membrane matrix. They required endothelial growth factors for growth and survival, and they could be induced to form tubular structures resembling blood vessels when cultured under low calcium conditions. The formation of vessel-like structures was blocked by nicotine, and restored by FK506, suggesting that 'nuclear factor of activated T cells' activity prevents differentiation of these cells. In summary, these cell lines represent a unique and novel resource to improve our understanding of endothelial cell biology in general and canine HSA in particular.

show abstract

Management of angiosarcoma

Cited by 87 publications

References 41 publications

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification

Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium

Contact Info

Product

Resources

About